LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

Search

Cerus Corp

Open

BrancheGesundheitswesen

1.31 -2.96

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.3

Max

1.33

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.2M

-7.7M

Verkäufe

-7.6M

43M

EPS

-0.04

Gewinnspanne

-17.85

Angestellte

614

EBITDA

-5.8M

-5.9M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+256.49% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

31. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-1.9M

258M

Vorheriger Eröffnungskurs

4.27

Vorheriger Schlusskurs

1.31

Nachrichtenstimmung

By Acuity

61%

39%

325 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Cerus Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2025, 23:20 UTC

Ergebnisse

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

13. Mai 2025, 23:48 UTC

Market Talk

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

13. Mai 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Mai 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

13. Mai 2025, 23:24 UTC

Market Talk
Ergebnisse

Global Equities Roundup: Market Talk

13. Mai 2025, 23:24 UTC

Market Talk
Ergebnisse

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

13. Mai 2025, 22:58 UTC

Ergebnisse

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. Mai 2025, 22:58 UTC

Ergebnisse

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

13. Mai 2025, 22:58 UTC

Ergebnisse

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

13. Mai 2025, 22:58 UTC

Ergebnisse

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

13. Mai 2025, 22:38 UTC

Ergebnisse

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

13. Mai 2025, 22:38 UTC

Ergebnisse

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

13. Mai 2025, 22:37 UTC

Ergebnisse

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

13. Mai 2025, 22:36 UTC

Ergebnisse

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

13. Mai 2025, 22:35 UTC

Ergebnisse

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

13. Mai 2025, 22:34 UTC

Ergebnisse

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

13. Mai 2025, 22:33 UTC

Ergebnisse

Aristocrat: Interactive Business Delivered Strong Revenue Growth

13. Mai 2025, 22:33 UTC

Ergebnisse

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

13. Mai 2025, 22:33 UTC

Ergebnisse

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

13. Mai 2025, 22:30 UTC

Ergebnisse

Aristocrat Interim Dividend 44 Australian Cents/Share

13. Mai 2025, 22:30 UTC

Ergebnisse

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

13. Mai 2025, 22:29 UTC

Ergebnisse

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

13. Mai 2025, 22:28 UTC

Ergebnisse

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

13. Mai 2025, 21:15 UTC

Ergebnisse

Nu Holdings 1Q Rev $3.2B >NU

13. Mai 2025, 21:03 UTC

Top News

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

13. Mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Mai 2025, 20:32 UTC

Ergebnisse

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

13. Mai 2025, 20:31 UTC

Ergebnisse

Alcon 1Q Sales $2.45B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q Rev $2.47B >ALC.EB

13. Mai 2025, 20:30 UTC

Ergebnisse

Alcon 1Q EPS 70c >ALC.EB

Peer-Vergleich

Kursveränderung

Cerus Corp Prognose

Kursziel

By TipRanks

256.49% Vorteil

12-Monats-Prognose

Durchschnitt 4.67 USD  256.49%

Hoch 5 USD

Tief 4 USD

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cerus Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

1.3 / 1.36Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

325 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.